Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: A retrospective multicenter study

Torres, Harrys A.; Nevah, Moises I.; Mahale, Parag; Kontoyiannis, Dimitrios P.; Hassan, Manal M.; Raad, Issam

doi:10.1016/j.jcv.2012.03.002

Cited by 12 publications

(6 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Second, in this study, we only included patients with genotype 1 and 4 infections. However, these genotypes are difficult to treat and common in HCV/HIV-coinfected individuals, 22 and therefore, TDM might be more beneficial for these genotypes. Third, this analysis was performed on RBV concentrations from patients treated with dual therapy.…”

Section: Discussionmentioning

confidence: 99%

Lower Ribavirin Plasma Concentrations in HCV/HIV–Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage

Deenen

Kanter

Dofferhoff

et al. 2015

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Lower Ribavirin Plasma Concentrations in HCV/HIV–Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage

Deenen

Kanter

Dofferhoff

et al. 2015

Therapeutic Drug Monitoring

View full text Add to dashboard Cite

show abstract

“…In a cellular model of HCV, NS3/4sA (an HCV viral protease) and NS5B (an RNA‐dependent RNA polymerase) impeded DNA repair via interaction with the ataxia telangiectasia mutated (ATM)‐driven response pathway . Selected genotypes of HCV also might be associated with the risk of developing HCC: greater carcinogenic potential has been reported for some variants, mostly genotypes 1 (1b) and 3, although definitive studies are lacking …”

Section: Mechanisms By Which Hcv Contributes To the Development Of Camentioning

confidence: 99%

The oncologic burden of hepatitis C virus infection: A clinical perspective

Torres

Shigle

Hammoudi

et al. 2017

CA A Cancer J Clinicians

Self Cite

110

View full text Add to dashboard Cite

Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer. Direct-acting antivirals (DAAs) have changed HCV treatment paradigms, but little is known about management of HCV infection in patients with cancer. The substantial burden of HCV infection in patients with cancer and the inconclusive evidence regarding detection and management of HCV infection in patients with cancer prompted us to review the literature and formulate recommendations. Patients for whom HCV screening is recommended included all patients with hematological malignancies, hematopoietic cell transplant candidates or patients with hepatocellular carcinoma (HCC). There is lack of consensus-based recommendations for the identification of other cancer patients but physicians may consider screening patients belonging to groups at heightened risk of HCV infection including persons born during 1945–1965 and those at high risk for infection. Patients with evidence of HCV infection should be assessed by an expert to evaluate liver disease severity, comorbidities associated with HCV infection, and treatment opportunities. DAA therapy should be tailored on the basis of patient prognosis, type of cancer, cancer treatment plan, and hepatic and virologic parameters. HCV-infected cancer patients with cirrhosis (or even advanced fibrosis) and those at risk for liver disease progression, especially patients with HCV-associated comorbidities, should have ongoing follow-up, regardless of whether there is a sustained virologic response, to ensure timely detection and treatment of HCC. HCV infection and its treatment should not be considered contraindications to cancer treatment and should not delay the initiation of an urgent cancer therapy.

show abstract

“…Interestingly, this genotype was associated with higher carcinogenic properties in immunocompetent patients [ 10 , 11 ]. Genotypes 2 and 3 were more prominent in immunocompromised patients, as the study revealed they were in greater occurrence in hepatocellular carcinoma and lymphoma as they had three times the risk of cancer than genotype 1 [ 12 ]. Our patient’s case is also unique because he was symptomatic in the initial days following transmission.…”

Section: Discussionmentioning

confidence: 99%

Acute Hepatitis C After Penile Stem Cell Injection

Zaveri¹,

Tagliaferri²,

Shah³

et al. 2022

Cureus

View full text Add to dashboard Cite

Hepatitis C is a viral infection that is transmitted via blood or other bodily fluids and usually manifests as a chronic infection. We present a unique case of acute hepatitis C from a penile stem cell injection. Although previous cases have reported the reactivation of chronic hepatitis C after hematopoietic stem cell transplantation, it is uncommon for hepatitis C to present acutely, especially in an immunocompetent patient. To our knowledge, this is the first case of acute hepatitis C after a penile stem cell injection.

show abstract

Hepatitis C virus genotype distribution varies by underlying disease status among patients in the same geographic region: A retrospective multicenter study

Cited by 12 publications

References 22 publications

Lower Ribavirin Plasma Concentrations in HCV/HIV–Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage

Lower Ribavirin Plasma Concentrations in HCV/HIV–Coinfected Patients Than in HCV-Monoinfected Patients Despite Similar Dosage

The oncologic burden of hepatitis C virus infection: A clinical perspective

Acute Hepatitis C After Penile Stem Cell Injection

Contact Info

Product

Resources

About